Drug
Ch14.18/CHO
Ch14.18/CHO is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_3
1
20%
Phase Distribution
3
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(2)
Other(1)
Detailed Status
Completed2
Active, not recruiting1
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Trials by Status
completed240%
active_not_recruiting120%
unknown120%
recruiting120%
Recent Activity
2 active trials
Showing 5 of 5
active_not_recruitingphase_1
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
NCT02914405
completedphase_2
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
NCT02258815
recruitingphase_3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01704716
completedphase_1
ch14.18/CHO Bridging Study
NCT01704872
unknownphase_1
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
NCT01701479
Clinical Trials (5)
Showing 5 of 5 trials
NCT02914405Phase 1
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
NCT02258815Phase 2
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
NCT01704716Phase 3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01704872Phase 1
ch14.18/CHO Bridging Study
NCT01701479Phase 1
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5